Career Enhancement Program

职业提升计划（CEP）的主要目的是吸引和培养杰出的 希望之城和亚拉巴马伯明翰大学的调查人员在进行杰出的 淋巴瘤转化研究。无论是初级研究人员还是资深研究人员， 或重新关注淋巴瘤可能参与。每年支持两个人， 两年招募希望从事淋巴瘤研究职业的研究人员可能会 也发生。SPORE预算的直接成本为每年50，000美元， City of Hope和UAB分别捐款10万美元和2.5万美元。调查人员 可以将资金用于受保护的研究时间、人员和用品的工资支持， 会议和培训费用。斯蒂芬·福尔曼博士亚历山德拉·莱文博士和斯米塔·巴蒂亚博士 集体代表广泛的指导经验，领导CEP。他们将引导 挑选受训人员、提供咨询意见和反馈意见以及协调年度 审查.通过各种媒体广泛传播方案公告，以确保 意识将作出持续、协调一致的努力，吸引妇女和少数族裔 候选人对申请人的审查是基于他们的资格、科学价值和 他们提出的项目的可行性，以及与其他有意义的互动的潜力 项目和核心内的孢子。学员将在资深教师中选择导师， SPORE成员;职业发展委员会必须批准选择， 可用于辅助匹配过程。学员提交书面进度报告两次 每年一次，详细介绍迄今为止的相关工作以及 他们的研究。获奖者在年度孢子务虚会上展示他们的研究。外部 咨询委员会评估进展情况，并在必要时寻求解决问题的办法。 以前的CEP接受者非常富有成效。王秀丽博士对公司的发展给予了高度评价。 具有双重特异性的嵌合抗原受体（CAR）T细胞的前景研究 巨细胞病毒和CD 19;这项调查已被提升为一个完整的项目， 当前孢子。伊丽莎白·布德博士进行的研究导致了一项针对CAR T细胞的试验。 针对急性髓系白血病中的CD123，她现在是项目4的临床负责人。 孢子。Alex Herrera博士现在是项目3的基本SPORE领导者， 研究生物标志物和接受细胞治疗的患者的结果的进展;两个主要的 翻译研究项目正在进行中。我们预计，新的一类调查人员将 继续执行尖端的传统，变革性淋巴瘤研究.

The primary aim of the Career Enhancement Program (CEP) is to attract and train exceptional investigators at City of Hope and University of Alabama Birmingham in conducting outstanding lymphoma translational research. Both junior and established researchers who desire to focus or refocus on lymphoma may participate. Two individuals are supported every year, for up to two years. Recruitment of investigators who wish to pursue a career in lymphoma research may also take place. SPORE has budgeted direct costs of $50,000 per year, with additional yearly contributions from City of Hope and UAB of $100,000 and $25,000, respectively. Investigators can use funds for salary support for protected research time, personnel and supplies, and meeting and training expenses. Drs. Stephen Forman, Alexandra Levine, and Smita Bhatia, collectively representing extensive mentoring experience, lead the CEP. They will direct the process of selecting trainees, providing advice and feedback, and coordinating an annual review. Program announcements are widely disseminated through various media to ensure awareness. A sustained, concerted effort will be made to attract women and minority candidates. Applicants are reviewed on the basis of their qualifications, the scientific merit and feasibility of their proposed project, and the potential for meaningful interaction with the other projects and cores within the SPORE. Trainees are to select mentors among senior faculty or SPORE members; the Career Enhancement Committee must approve the choice and is available for assisting the matching process. Trainees submit a written progress report twice annually, detailing relevant work to date and manuscripts and presentations that arose from their research. Awardees present their research at the annual SPORE retreat. The External Advisory Board evaluates progress and seeks solutions to points of concern if necessary. Previous CEP recipients have been greatly productive. Dr. Xiuli Wang conducted highly promising research on chimeric antigen receptor (CAR) T cells redirected with dual specificity for cytomegalovirus and CD19; this investigation has been promoted to a full project within the current SPORE. Dr. Elizabeth Budde performed studies that led to a CAR T cell trial directed against CD123 in acute myeloid leukemia, and she is now the clinical lead in Project 4 of the SPORE. Dr. Alex Herrera, now a basic SPORE leader in Project 3, has made significant progress studying biomarkers and outcome in patients who undergo cellular therapies; two main translational research projects are ongoing. We anticipate that the new class of investigators will continue the tradition of performing cutting-edge, transformative lymphoma research.